![Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F61682.jpg&w=3840&q=50)
Elevated Serum Uric Acid and Cardiovascular Disease: A Review and Potential Therapeutic Interventions
Michael Freilich1, Andrew Arredondo1, Seyedeh Leila Zonnoor1
1Internal Medicine, State University of New York Downstate Health Sciences University, Brooklyn, USA.
Insights
Elevated serum uric acid (SUA) is linked to cardiovascular disease (CVD). Optimizing medication to control inflammation may improve outcomes for patients with hyperuricemia and CVD.
Area of Science:
- Cardiology
- Nephrology
- Rheumatology
Background:
- Elevated serum uric acid (SUA) is associated with cardiovascular disease (CVD), including hypertension (HTN), coronary artery disease (CAD), and heart failure (HF).
- The precise mechanisms linking hyperuricemia and CVD are not fully elucidated but are thought to involve systemic inflammation.
Purpose of the Study:
- To review the current understanding of the association between hyperuricemia and CVD.
- To examine recent clinical trials on anti-inflammatory medications' effects on cardiovascular events.
- To discuss optimizing medication regimens for patients with elevated SUA to reduce CVD morbidity and mortality.
Main Methods:
- Literature review of landmark studies and recent clinical trials.
- Analysis of the role of systemic inflammation in hyperuricemia-related CVD.
- Discussion of evidence-based medication optimization strategies.
Main Results:
- The link between hyperuricemia and CVD is well-established, with inflammation playing a potential role.
- Controlling inflammation shows promise in improving cardiovascular outcomes.
- Anti-inflammatory therapies are being investigated for their impact on cardiovascular events.
Conclusions:
- Optimizing medication regimens to manage inflammation in patients with elevated SUA is crucial for decreasing CVD morbidity and mortality.
- Further research into anti-inflammatory strategies is warranted for this patient population.
Abstract:
Several landmark studies found a relationship between elevated serum uric acid (SUA) levels and cardiovascular disease (CVD). In fact, the association between hyperuricemia and hypertension (HTN), coronary artery disease (CAD), and heart failure (HF) is currently well-established. While the mechanism linking hyperuricemia and CVD is not fully known, a systemic inflammatory response by the host is believed to play a role. With the goal of decreasing the morbidity and mortality of CVD in patients with hyperuricemia, the focus has now turned to properly optimizing a medication regimen for this patient population. Recent studies have shown that controlling underlying inflammation can, in fact, lead to better cardiovascular outcomes for populations with acute and chronic coronary disease. In this paper, we will discuss the current state of understanding on the association of hyperuricemia and cardiovascular disease. Furthermore, we will look into the most recent clinical trials showing the effects anti-inflammatory medications have on both decreasing and recovering from cardiovascular events. We will conclude with a discussion on, given the information mentioned above, how to properly optimize a medication regimen in patients with elevated SUA levels with a focus on decreasing the morbidity and mortality associated with CVD.
Related Concept Videos
01:26Atherosclerosis III: Management
01:30Coronary Artery Disease I: Introduction
01:26Coronary Artery Disease IV: Preventive Measures
01:27Peripheral Artery Disease III: Interprofessional Care
01:21Rheumatic Heart Disease III: Medical Management
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents